Skip to main content
Homepage
PARTIAL Analysis Report
Sep 4, 2026
58 days ago · 2% complete
Partial analysis — no complete end-to-end run on record.
No report run on this ticker yet Only preliminary foundational data below
NOT YET RESEARCHED No report has been run on VCEL yet. What you are seeing is foundational data only — price, profile and filings — not the full analysis (lenses, memo, scores and the AI panel arrive with the first report).
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Vericel Corporation (VCEL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at voiceoftrades.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Vericel Corporation

VCEL NASDAQ
Healthcare · Biotechnology
Cambridge, MA 02139, United States vcel.com Updated Nov 1, 8:14pm
Price
$40.19
Market Cap
$2.1B
Employees
357
Beta
1.07
Avg Volume
487,222
CEO
Mr. Dominick C. Colangelo Esq.

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries. Its commercial portfolio includes MACI, a cell therapy used in knee cartilage repair; Epicel, a skin replacement product for severe burns; and NexoBrid, an enzymatic biologic used for eschar removal in burn care. The company serves hospitals, surgeons, and specialized care teams across the United States, with its products positioned within regenerative medicine and acute wound care. Vericel’s business centers on translating cell-based science into practical treatments for complex orthopedic and burn-related conditions.

Runs with full report
Price Overview
Current data · timestamped when a report runs
$39.75
Change
+0.15 (+0.37%)
Day Range
$38.55 – $40.14
52-Week Range
$28.95 – $49.32
50-Day MA
$43.88
200-Day MA
$38.14
Volume
33,101.00
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 1 computed · 6 not applicable · 17 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VCEL — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for VCEL — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for VCEL — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for VCEL — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for VCEL. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this